Breitz H B, Fisher D R, Wessels B W
NeoRx/Virginia Mason Clinical Research Unit, Virginia Mason Medical Center, Seattle, Washington 98101, USA.
J Nucl Med. 1998 Oct;39(10):1746-51.
Estimates of radiation absorbed dose to the red marrow (RM) would be valuable in treatment planning for radioimmunotherapy if they could show a correlation with clinical toxicity. In this study, a correlation analysis was performed to determine whether estimates of radiation absorbed dose to the bone marrow could accurately predict marrow toxicity in patients who had received 186Re-labeled monoclonal antibody.
White blood cell and platelet count data from 25 patients who received 186Re-NR-LU-10 during Phase I radioimmunotherapy trials were analyzed, and the toxicity grade, the fraction of the baseline counts at the nadir (percentage baseline) and the actual nadir were used as the indicators of marrow toxicity. Toxicity was correlated with various predictors of toxicity. These predictors included the absorbed dose to RM, the absorbed dose to whole body (WB) and the total radioactivity administered.
Percentage baseline and grade of white blood cells and platelets all showed a moderate correlation with absorbed dose and radioactivity administered (normalized for body size). The percentage baseline platelet count was the indicator of toxicity that achieved the highest correlation with the various predictors of toxicity (r = 0.73-0.79). The estimated RM absorbed dose was not a better predictor of toxicity than either the WB dose or the total radioactivity administered. There was substantial variation in the blood count response of the patients who were administered similar radioactivity doses and who had similar absorbed dose estimates.
Although there was a moderately good correlation of toxicity with dose, the value of the dose estimates in predicting toxicity is limited by the patient-to-patient variability in response to internally administered radioactivity. In this analysis of patients receiving 186Re-labeled monoclonal antibody, a moderate correlation of toxicity with dose was observed but marrow dose was of limited use in predicting toxicity for individual patients.
如果对红骨髓(RM)的辐射吸收剂量估计能显示出与临床毒性的相关性,那么它在放射免疫治疗的治疗计划中将会很有价值。在本研究中,进行了相关性分析,以确定对骨髓辐射吸收剂量的估计是否能准确预测接受¹⁸⁶Re标记单克隆抗体治疗患者的骨髓毒性。
分析了25例在I期放射免疫治疗试验中接受¹⁸⁶Re-NR-LU-10治疗患者的白细胞和血小板计数数据,并将毒性分级、最低点时基线计数的分数(基线百分比)和实际最低点作为骨髓毒性指标。将毒性与各种毒性预测指标进行相关性分析。这些预测指标包括对RM的吸收剂量、对全身(WB)的吸收剂量以及给予的总放射性活度。
白细胞和血小板的基线百分比及分级均与吸收剂量和给予的放射性活度(根据身体大小进行标准化)呈现中度相关性。基线血小板计数百分比是与各种毒性预测指标相关性最高的毒性指标(r = 0.73 - 0.79)。估计的RM吸收剂量在预测毒性方面并不比WB剂量或给予的总放射性活度更好。给予相似放射性活度剂量且吸收剂量估计相似的患者,其血细胞计数反应存在很大差异。
尽管毒性与剂量存在中度良好的相关性,但剂量估计在预测毒性方面的价值受到患者对体内给予放射性活度反应的个体差异限制。在对接受¹⁸⁶Re标记单克隆抗体治疗患者的这项分析中,观察到毒性与剂量存在中度相关性,但骨髓剂量在预测个体患者毒性方面的作用有限。